474 related articles for article (PubMed ID: 28865178)
1. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
2. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
3. In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells.
Xu L; Shen M; Chen X; Yang DR; Tsai Y; Keng PC; Lee SO; Chen Y
Exp Cell Res; 2018 Mar; 364(1):113-123. PubMed ID: 29408565
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
Xu LJ; Ma Q; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 Jun; 17(6):8111-8120. PubMed ID: 29693186
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
[TBL] [Abstract][Full Text] [Related]
6. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract][Full Text] [Related]
7. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
Zhang L; Xu LJ; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 May; 17(5):7045-7054. PubMed ID: 29568923
[TBL] [Abstract][Full Text] [Related]
8. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
[TBL] [Abstract][Full Text] [Related]
9. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
12. Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells.
Shen M; Chen Y; Xu L; Zhu R; Xue X; Tsai Y; Keng PC; Lee SO; Chen Y
Int J Oncol; 2018 Jul; 53(1):317-328. PubMed ID: 29750425
[TBL] [Abstract][Full Text] [Related]
13. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.
Shen MJ; Xu LJ; Yang L; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Oncotarget; 2017 Oct; 8(46):80506-80520. PubMed ID: 29113321
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
15. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo.
Yoneda T; Kunimura N; Kitagawa K; Fukui Y; Saito H; Narikiyo K; Ishiko M; Otsuki N; Nibu KI; Fujisawa M; Serada S; Naka T; Shirakawa T
Cancer Gene Ther; 2019 Nov; 26(11-12):388-399. PubMed ID: 30607005
[TBL] [Abstract][Full Text] [Related]
17. NKG2D Signaling between Human NK Cells Enhances TACE-Mediated TNF-α Release.
Sharma N; Trinidad CV; Trembath AP; Markiewicz MA
J Immunol; 2017 Oct; 199(8):2865-2872. PubMed ID: 28893955
[TBL] [Abstract][Full Text] [Related]
18. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
19. FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells.
Shen M; Tsai Y; Zhu R; Keng PC; Chen Y; Chen Y; Lee SO
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Mar; 1863(3):313-322. PubMed ID: 29306075
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
